Masliah; Eliezer

Patent Applications and Registrations

Patent applications and USPTO patent grants for Masliah; Eliezer.The latest application filed is for "prevention and treatment of synucleinopathic and amyloidogenic disease".

Company Profile

4.19.25

Masliah; Eliezer - La Jolla CA
Masliah; Eliezer - San Diego CA
Masliah; Eliezer - Chula Vista CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them Grant 10,947,302 - Masliah , et al. March 16, 2	2021-03-16
Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease App 20210032318 - Schenk; Dale B. ; et al.	2021-02-04
Compositions Targeting 3-repeat Tau For The Treatment Of Neurodegenerative Disorders, And Methods For Making And Using Them App 20200181245 - MASLIAH; Eliezer ; et al.	2020-06-11
Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease App 20190300598 - SCHENK; DALE B. ; et al.	2019-10-03
Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease App 20170349651 - Schenk; Dale B. ; et al.	2017-12-07
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease App 20160184416 - Schenk; Dale B. ; et al.	2016-06-30
Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease App 20160060331 - Schenk; Dale B. ; et al.	2016-03-03
Compounds for reversing and inhibiting protein aggregation, and methods for making and using them Grant 8,946,165 - Masliah , et al. February 3, 2	2015-02-03
Compound Suitable For The Treatment Of Synucleopathies App 20140364610 - MASLIAH; Eliezer ; et al.	2014-12-11
Compound suitable for the treatment of synucleopathies Grant 8,846,682 - Masliah , et al. September 30, 2	2014-09-30
Prevention and treatment of synucleinopathic and amyloidogenic disease Grant 8,697,082 - Schenk , et al. April 15, 2	2014-04-15
Prevention and treatment of synucleinopathic and amyloidogenic disease Grant 8,506,959 - Schenk , et al. August 13, 2	2013-08-13
Compounds for inhibiting protein aggregation, and methods for making and using them Grant 8,450,481 - Masliah , et al. May 28, 2	2013-05-28
Compound Suitable for the Treatment of Synucleopathies App 20130035342 - Masliah; Eliezer ; et al.	2013-02-07
Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease App 20120201842 - Schenk; Dale B. ; et al.	2012-08-09
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease App 20120142902 - Schenk; Dale B. ; et al.	2012-06-07
Prevention and treatment of synucleinopathic and amyloidogenic disease Grant 8,147,833 - Schenk , et al. April 3, 2	2012-04-03
Compounds For Reversing And Inhibiting Protein Aggregation, And Methods For Making And Using Them App 20110223240 - Masliah; Eliezer ; et al.	2011-09-15
Prevention And Treatment Of Synucleinopathic Disease App 20110135660 - Schenk; Dale B. ; et al.	2011-06-09
Transgenic mice for screening for inhibitors of protein aggregation and methods for making and using them Grant 7,795,495 - Masliah , et al. September 14, 2	2010-09-14
Compounds For Inhibiting Protein Aggregation, And Methods For Making And Using Them App 20100226969 - Masliah; Eliezer ; et al.	2010-09-09
Treatment and delay of outset of Parkinson's disease Grant 7,727,957 - Schenk , et al. June 1, 2	2010-06-01
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease App 20100086545 - Schenk; Dale B. ; et al.	2010-04-08
Prevention and treatment of synucleinopathic and amyloidogenic disease App 20100031377 - Schenk; Dale B ; et al.	2010-02-04
Human .alpha. synuclein expressing transgenic mice Grant 7,459,601 - Masliah , et al. December 2, 2	2008-12-02
Transgenic mouse model for neurodegenerative diseases Grant 7,393,994 - Masliah , et al. July 1, 2	2008-07-01
Method For Screening For Anti-amyloidogenic Properties And Method For Treatment Of Neurodegenerative Disease App 20080051337 - Masliah; Eliezer ; et al.	2008-02-28
Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents Grant 7,276,643 - Masliah , et al. October 2, 2	2007-10-02
Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease Grant 7,226,746 - Masliah , et al. June 5, 2	2007-06-05
Prevention and treatment of synucleinopathic and amyloidogenic disease App 20060058233 - Schenk; Dale B. ; et al.	2006-03-16
Transgenic animals and methods for screening for anti-amyloidogenic agents and agents for treating neurodegenerative disease App 20050086711 - Masliah, Eliezer ; et al.	2005-04-21
Prevention and treatment of synucleinopathic and amyloidogenic disease App 20050037013 - Schenk, Dale B. ; et al.	2005-02-17
Prevention and treatment of synucleinopathic disease App 20040146521 - Schenk, Dale B. ; et al.	2004-07-29
Prevention and treatment of synucleinopathic disease App 20040136993 - Schenk, Dale B. ; et al.	2004-07-15
Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease App 20040128706 - Masliah, Eliezer ; et al.	2004-07-01
Development of transgenic model for interventions in neurodegenerative diseases App 20030056231 - Masliah, Eliezer ; et al.	2003-03-20
Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy Grant 6,175,057 - Mucke , et al. January 16, 2	2001-01-16

Company Registrations

NCAGE Code	4BYK7	MASLIAH ELIEZER
CAGE Code	4BYK7	MASLIAH, ELIEZER

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.